• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 mRNA 疫苗可快速稳定地动员 CD8 T 细胞。

Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine.

机构信息

Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Faculty of Biology, University of Freiburg, Freiburg, Germany.

出版信息

Nature. 2021 Sep;597(7875):268-273. doi: 10.1038/s41586-021-03841-4. Epub 2021 Jul 28.

DOI:10.1038/s41586-021-03841-4
PMID:34320609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8426185/
Abstract

SARS-CoV-2 spike mRNA vaccines mediate protection from severe disease as early as ten days after prime vaccination, when neutralizing antibodies are hardly detectable. Vaccine-induced CD8 T cells may therefore be the main mediators of protection at this early stage. The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. Here we show on a single-epitope level that a stable and fully functional CD8 T cell response is vigorously mobilized one week after prime vaccination with bnt162b2, when circulating CD4 T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion that generated highly differentiated effector CD8 T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared with natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8 T cells are important effector cells, are expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination.

摘要

SARS-CoV-2 刺突 mRNA 疫苗在初次接种后 10 天左右就可以介导对严重疾病的保护,此时几乎检测不到中和抗体。因此,疫苗诱导的 CD8 T 细胞可能是早期保护的主要介导者。然而,它们的诱导细节、与自然感染的比较以及与疫苗诱导免疫的其他方面的关联仍然不完全清楚。在这里,我们在单个表位水平上表明,在初次接种 bnt162b2 一周后,就会强烈动员出稳定且功能齐全的 CD8 T 细胞反应,而此时循环中的 CD4 T 细胞和中和抗体仍难以检测到。加强接种诱导了强烈的扩增,产生了高度分化的效应 CD8 T 细胞;然而,功能能力和记忆前体细胞池都没有受到影响。与自然感染相比,疫苗诱导的早期记忆 T 细胞表现出相似的功能能力,但亚群分布不同。我们的研究结果表明,CD8 T 细胞是重要的效应细胞,在初次接种后的早期保护窗内被扩增,先于疫苗诱导免疫的其他效应臂的成熟,并在加强接种后稳定维持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/428bbd026390/41586_2021_3841_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ec9991eeeb26/41586_2021_3841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/e210f5cab6cc/41586_2021_3841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/82ef1203bbb3/41586_2021_3841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/47607d097193/41586_2021_3841_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ac888f67ffed/41586_2021_3841_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/2e8dde3fed7d/41586_2021_3841_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/59d9eb47a994/41586_2021_3841_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/f31fe801fb0e/41586_2021_3841_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/da9d4d8d275f/41586_2021_3841_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ac22c50cffba/41586_2021_3841_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/c5ac0fb9519c/41586_2021_3841_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/9186110361e9/41586_2021_3841_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/4e0f8a6eab06/41586_2021_3841_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/428bbd026390/41586_2021_3841_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ec9991eeeb26/41586_2021_3841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/e210f5cab6cc/41586_2021_3841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/82ef1203bbb3/41586_2021_3841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/47607d097193/41586_2021_3841_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ac888f67ffed/41586_2021_3841_Fig5_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/2e8dde3fed7d/41586_2021_3841_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/59d9eb47a994/41586_2021_3841_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/f31fe801fb0e/41586_2021_3841_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/da9d4d8d275f/41586_2021_3841_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/ac22c50cffba/41586_2021_3841_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/c5ac0fb9519c/41586_2021_3841_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/9186110361e9/41586_2021_3841_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/4e0f8a6eab06/41586_2021_3841_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac51/8426185/428bbd026390/41586_2021_3841_Fig14_ESM.jpg

相似文献

1
Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine.SARS-CoV-2 mRNA 疫苗可快速稳定地动员 CD8 T 细胞。
Nature. 2021 Sep;597(7875):268-273. doi: 10.1038/s41586-021-03841-4. Epub 2021 Jul 28.
2
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.BNT162b2 疫苗可在人体内诱导中和抗体和多特异性 T 细胞。
Nature. 2021 Jul;595(7868):572-577. doi: 10.1038/s41586-021-03653-6. Epub 2021 May 27.
3
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.针对 SARS-CoV-2 的合成肽疫苗的临床前评估,该疫苗可诱导多表位和交叉反应性体液中和以及细胞 CD4 和 CD8 反应。
Emerg Microbes Infect. 2021 Dec;10(1):1931-1946. doi: 10.1080/22221751.2021.1978823.
4
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
5
Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.新冠病毒 mRNA 疫苗接种后 T 细胞和 B 细胞受体库的单细胞分析。
JCI Insight. 2021 Dec 22;6(24):e153201. doi: 10.1172/jci.insight.153201.
6
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
7
Rapid induction of antigen-specific CD4 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination.快速诱导抗原特异性 CD4 T 细胞与对 SARS-CoV-2 mRNA 疫苗接种的协调体液和细胞免疫有关。
Immunity. 2021 Sep 14;54(9):2133-2142.e3. doi: 10.1016/j.immuni.2021.08.001. Epub 2021 Aug 13.
8
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.BNT162b 疫苗可保护恒河猴免受 SARS-CoV-2 感染。
Nature. 2021 Apr;592(7853):283-289. doi: 10.1038/s41586-021-03275-y. Epub 2021 Feb 1.
9
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.与年龄相关的对 SARS-CoV-2 疫苗 BNT162b2 的免疫反应异质性。
Nature. 2021 Aug;596(7872):417-422. doi: 10.1038/s41586-021-03739-1. Epub 2021 Jun 30.
10
Immune Response to COVID-19 Vaccination in Elite Athletes.精英运动员对 COVID-19 疫苗接种的免疫反应。
Exerc Immunol Rev. 2024;30:63-70.

引用本文的文献

1
Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.mRNA和腺病毒COVID-19疫苗接种后髓系细胞中剂量依赖性干扰素程序
bioRxiv. 2025 Aug 18:2025.08.15.668720. doi: 10.1101/2025.08.15.668720.
2
Bivalent mRNA booster encoding virus-like particles elicits potent polyclass RBD antibodies in pre-vaccinated mice.编码病毒样颗粒的二价mRNA加强针在预先接种疫苗的小鼠中引发强效多类RBD抗体。
bioRxiv. 2025 Aug 19:2025.08.18.670983. doi: 10.1101/2025.08.18.670983.
3
Decrypting the Immune Symphony for RNA Vaccines.

本文引用的文献

1
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.SARS-CoV-2 mRNA 疫苗可诱导持久的人体生发中心反应。
Nature. 2021 Aug;596(7870):109-113. doi: 10.1038/s41586-021-03738-2. Epub 2021 Jun 28.
2
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.BNT162b2 疫苗可在人体内诱导中和抗体和多特异性 T 细胞。
Nature. 2021 Jul;595(7868):572-577. doi: 10.1038/s41586-021-03653-6. Epub 2021 May 27.
3
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
解读RNA疫苗的免疫乐章
Vaccines (Basel). 2025 Aug 20;13(8):882. doi: 10.3390/vaccines13080882.
4
SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression.严重急性呼吸综合征冠状病毒2型非结构蛋白1是主要组织相容性复合体I类和II类表达的主要抑制因子。
Viruses. 2025 Aug 5;17(8):1083. doi: 10.3390/v17081083.
5
Human tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1.人类扁桃体类器官揭示了调节对ChAdOx1体液和细胞反应的固有途径。
PLoS Pathog. 2025 Aug 22;21(8):e1013432. doi: 10.1371/journal.ppat.1013432. eCollection 2025 Aug.
6
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.T细胞表位图谱分析揭示了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)蛋白质组中进化保守区域的免疫显性。
iScience. 2025 Jul 2;28(8):113044. doi: 10.1016/j.isci.2025.113044. eCollection 2025 Aug 15.
7
The impact of vaccine booster doses on specific B- and T-lymphocyte dynamics in Thai healthcare personnel following COVID-19 vaccination.新冠疫苗接种后,加强针剂量对泰国医护人员特定B淋巴细胞和T淋巴细胞动态变化的影响
Sci Rep. 2025 Jul 16;15(1):25713. doi: 10.1038/s41598-025-10400-8.
8
Epitope and HLA specificity of human TCRs against Plasmodium falciparum circumsporozoite protein.人类针对恶性疟原虫环子孢子蛋白的T细胞受体的表位与HLA特异性
J Exp Med. 2025 Sep 1;222(9). doi: 10.1084/jem.20250044. Epub 2025 Jul 10.
9
Changes in peripheral blood mononuclear cell electrical properties in response to viral exposure and vaccination.外周血单个核细胞电特性对病毒暴露和疫苗接种的反应变化。
Sci Rep. 2025 Jul 9;15(1):24583. doi: 10.1038/s41598-025-08724-6.
10
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.评估单剂次加强剂量的AVX/COVID-12疫苗的安全性、免疫原性和非劣效性的2/3期研究。
Sci Adv. 2025 Jun 27;11(26):eadq2887. doi: 10.1126/sciadv.adq2887.
mRNA 疫苗接种后 SARS-CoV-2 初免者和康复者的抗体和记忆 B 细胞反应存在差异。
Sci Immunol. 2021 Apr 15;6(58). doi: 10.1126/sciimmunol.abi6950.
4
Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.早期 T 细胞和结合抗体反应与 COVID-19 RNA 疫苗疗效的出现有关。
Med. 2021 Jun 11;2(6):682-688.e4. doi: 10.1016/j.medj.2021.04.003. Epub 2021 Apr 8.
5
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.SARS-CoV-2 B.1.1.7 对 mRNA 疫苗诱导抗体的敏感性。
Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.
6
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.SARS-CoV-2 mRNA 疫苗可促进与中和抗体产生相关的强效抗原特异性生发中心反应。
Immunity. 2020 Dec 15;53(6):1281-1295.e5. doi: 10.1016/j.immuni.2020.11.009. Epub 2020 Nov 21.
10
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.